Esketamine Nasal Spray Market Analysis

Type (General Anaesthetics, Treatment-Resistant Depression)

The treatment-resistant depression segment in the esketamine nasal spray market is anticipated to grow massively during the forecast period and is expected to have a revenue share of around 63% by the end of 2036 in the market. The surge in the frequency of treatment-resistant depression and the existence of few treatment choices has further stimulated the market players to begin research and development activities in full bloom. For instance, an open-label, global study released on October 04, 2023, discovered that patients getting SPRAVATO (esketamine) CIII nasal spray for treatment-resistant depression (TRD) were 1.54 times as possibly to get remission after eight weeks than those cured with quetiapine extended-release (XR) at Week 8. The rising occurrence of treatment-resistant depression has created awareness concerning its therapy. Various market players are making progressed medications that can be managed through nasal and intravenous routes instead of the conventional oral route of administration. The increasing growth of novel therapeutics implemented for the therapy of resistant depression by market players to launch their novel materials is projected to lift the esketamine nasal spray market.

Patient (Adult, Pediatric, Geriatric)

The adult segment is estimated to hold 59% share of the global esketamine nasal spray market by 2036. The reason behind this growth is completely due to the prevalence of adult depression across the world. About 5% of adults internationally have depression. That number is likely even higher as not everyone who has depression obtains an official diagnosis. In fact, according to the study' 50% of mental health problems are established by age 14 and 75% by age 24. Young adults 18 to 25 years old are at the highest risk of a major gloomy episode per a report from the National Institute of Mental Health. Most people take time to come to terms with nerve-racking events, like mourning or a relationship failure. When these nerve-racking events appear, the risk of becoming depressed is enhanced if an individual stops meeting with friends and family and tries to work with their issues on their own.

Our in-depth analysis of the global esketamine nasal spray market includes the following segments: